Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance

By: via Benzinga
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that the European Medicines Agency (EMA) has informed the Company, through ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.